CoChat

Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program

Open access
Oshima, Megumi, Neal, Bruce, Toyama, Tadashi, Ohkuma, Toshiaki, Li, Qiang, de Zeeuw, Dick, Heerspink, Hiddo J.L., Mahaffey, Kenneth W., Fulcher, Gregory, Canovatchel, William, Matthews, David R., Perkovic, Vlado · 2020 · Journal of the American Society of Nephrology
Cited by 23

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Significance Statement: Traditionally, clinical trials studying effects of new therapies on renal outcome use the doubling of serum creatinine (equivalent to a 57% eGFR reduction) as an end point, requiring large sample sizes. Use of lesser eGFR reductions has been proposed, but few studies have evaluated their reliability. In this post hoc study of two multicenter, randomized trials, a greater number of observed events resulted from use of 50%, 40%, and 30% eGFR reductions compared with a 57% eGFR reduction. Observed effect sizes for canagliflozin versus placebo were attenuated when lesser eGFR reductions were used, likely because of canagliflozin’s acute effect on eGFR. However, if analyses control for this acute effect, lesser eGFR decline thresholds may be preferred to identify renoprotective effects of potential therapies because much smaller sample sizes can be used. Background: Traditionally, clinical trials evaluating effects of a new therapy with creatinine-based renal end points use doubling of serum creatinine (equivalent to a 57% eGFR reduction), requiring large sample sizes. Methods: To assess whether eGFR declines <57% could detect canagliflozin’s effects on renal outcomes, we conducted a post hoc study comparing effects of canagliflozin versus placebo on composite renal outcomes using sustained 57%, 50%, 40%, or 30% eGFR reductions in conjunction with ESKD and renal death. Because canagliflozin causes an acute reversible hemodynamic decline in eGFR, we made estimates using all eGFR values as well as estimates that excluded early measures of eGFR influenced by the acute hemodynamic effect. Results: Among the 10,142 participants, 93 (0.9%), 161 (1.6%), 352 (3.5%), and 800 (7.9%) participants recorded renal outcomes on the basis of 57%, 50%, 40%, or 30% eGFR reduction, respectively, during a mean follow-up of 188 weeks. Compared with a 57% eGFR reduction (risk ratio [RR], 0.51; 95% confidence interval [95% CI], 0.34 to 0.77), the effect sizes were progressively attenuated when using 50% (RR, 0.61; 95% CI, 0.45 to 0.83), 40% (RR, 0.70; 95% CI, 0.57 to 0.86), or 30% (RR, 0.81; 95% CI, 0.71 to 0.93) eGFR reductions. In analyses that controlled for the acute hemodynamic fall in eGFR, effect sizes were comparable, regardless of whether a 57%, 50%, 40%, or 30% eGFR reduction was used. Estimated sample sizes for studies on the basis of lesser eGFR reductions were much reduced by controlling for this early hemodynamic effect. Conclusions: Declines in eGFR <57% may provide robust estimates of canagliflozin’s effects on renal outcomes if the analysis controls for the drug’s acute hemodynamic effect. Clinical Trial registry name and registration number: CANagliflozin cardioVascular Assessment Study (CANVAS), NCT01032629 and CANVAS-R, NCT01989754.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2019121312

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 23

Metadata

Authors
Oshima, M., Neal, B., Toyama, T., Ohkuma, T., Li, Q., de Zeeuw, D., Heerspink, H. J. L., Mahaffey, K. W., Fulcher, G., Canovatchel, W., Matthews, D. R., & Perkovic, V.
Venue
Journal of the American Society of Nephrology
Published
2020-07-21
Volume
31
Issue
10
Pages
2446-2456
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W3045417598
Cited by
23
References
13
FWCI
2.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. https://app.cochat.ai/papers/10.1681/asn.2019121312
The paper
Oshima, M., Neal, B., Toyama, T., Ohkuma, T., Li, Q., de Zeeuw, D., Heerspink, H. J. L., Mahaffey, K. W., Fulcher, G., Canovatchel, W., Matthews, D. R., & Perkovic, V. (2020). Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2019121312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.